Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-REG: Cyclophosphamide and Sirolimus With or Without Azacitidine for Steroid-refractory Acute GVHD
NCT01453140Phase 2Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Aug 2011
- Primary completion
- Mar 2012
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin, azacitidine in graft-versus-host disease (GVHD), sponsored by Hackensack Meridian Health. Started Aug 2011; status: terminated.
02
Drugs
aldesleukinazacitidine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01453140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453140.